Aclaris Therapeutics Inc ACRS announced the publication of the Phase 2a trial results of ATI-1777 in moderate to severe atopic dermatitis (AD) in the peer-reviewed journal JID Innovations.
In the Phase 2a study, ATI-1777 demonstrated meaningful improvement in the modified Eczema Area and Severity Index over four weeks of treatment and minimal measurable systemic exposure with a 2% formulation applied twice daily.
Aclaris progressed ATI-1777 into a Phase 2b trial in patients with mild to severe AD. Topline results from this trial are expected in January 2024.
Aclaris also said it plans to explore the use of zunsemetinib (ATI-450) instead of ATI-2231 as a potential treatment for pancreatic and metastatic breast cancer, as well as in preventing bone loss in metastatic breast cancer patients.
The company is reassessing the most effective pathway for ATI-2138, including the indication selection, due to the evolving competitive landscape within ulcerative colitis. Aclaris plans to provide further guidance in early 2024.
In addition, Aclaris has approved a plan to reduce its workforce by approximately 46%. Aclaris anticipates this reduction will begin immediately and will be substantially complete by June 30, 2024.
"With the discontinuation of development of ATI-450 for immuno-inflammatory disease indications, we are taking steps to reduce our spending and streamline our organization, which we expect to meaningfully preserve capital," stated Douglas Manion, Aclaris' CEO.
Price Action: ACRS shares are down 16.70% at $0.85 on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
